Sonia Sharma, MD
Endocrinology, Diabetes & Metabolism · Sarasota, FLNPI 1043577794
Payments from drug & device makers
Across 321 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$924
- Lilly USA, LLC$818
- Dexcom, Inc.$680
- Sanofi-aventis U.S. LLC$638
- Tandem Diabetes Care, Inc.$438
- Novo Nordisk$425
- plus $4K from 34 others
What the payments were for
- Food & beverage$7,591100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 21 | $924 |
| Lilly USA, LLC | 34 | $818 |
| Dexcom, Inc. | 32 | $680 |
| Sanofi-aventis U.S. LLC | 26 | $638 |
| Tandem Diabetes Care, Inc. | 9 | $438 |
| Novo Nordisk | 20 | $425 |
| Corcept Therapeutics | 18 | $352 |
| AstraZeneca(2 entities) | 16 | $342 |
| AbbVie | 13 | $280 |
| Amgen(2 entities) | 14 | $273 |
| Xeris Pharmaceuticals, Inc. | 10 | $226 |
| Recordati_rare_diseases_inc. | 7 | $183 |
| Nevro Corp. | 8 | $181 |
| Boehringer Ingelheim | 8 | $167 |
| Radius Health, Inc. | 8 | $155 |
| Abbott | 7 | $151 |
| Amneal Pharmaceuticals LLC | 7 | $132 |
| Merck | 6 | $126 |
| Insulet Corporation | 6 | $124 |
| Almatica Pharma LLC | 6 | $109 |
| Ascendis Pharma Endocrinology Inc | 4 | $99 |
| BETA Bionics, Inc. | 6 | $86 |
| IBSA Pharma Inc. | 5 | $84 |
| Medtronic(2 entities) | 5 | $80 |
| Antares Pharma, Inc. | 3 | $61 |
| Ultragenyx Pharmaceutical Inc. | 3 | $60 |
| GRT US Holding, Inc. | 2 | $51 |
| Pfizer | 2 | $49 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Sequel Med Tech, LLC | 2 | $38 |
| Clarus Therapeutics Inc. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Sandoz | 1 | $25 |
| EUSA Pharma (US) LLC | 1 | $25 |
| Averitas Pharma Inc. | 1 | $22 |
| Lifescan, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Cequr Corporation | 1 | $18 |
| Novartis | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,595 in reported general payments places this provider in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 252 | $316,325 |
| MounjaroTirzepatide | 230 | $316,064 |
| JardianceEmpagliflozin | 118 | $135,988 |
| TrulicityDulaglutide | 72 | $111,590 |
| FarxigaDapagliflozin Propanediol | 81 | $97,323 |
| Teriparatide | 12 | $92,580 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $84,074 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $81,350 |
| JanuviaSitagliptin Phosphate | 44 | $49,564 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $39,000 |
| TymlosAbaloparatide | 14 | $37,637 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 35 | $37,170 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $36,591 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $34,096 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $26,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $818 | $435,603341 claims |
| Novo NordiskOzempic, Rybelsus | $425 | $341,364267 claims |
| Boehringer IngelheimJardiance, Tradjenta | $167 | $143,218130 claims |
| AstraZenecaFarxiga | $342 | $97,32381 claims |
| MerckJanuvia | $126 | $49,56444 claims |
| Radius Health, Inc.Tymlos | $155 | $37,63714 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $638 | $37,17035 claims |
| BayerKerendia | $924 | $13,19912 claims |
| AbbVieSynthroid, Armour Thyroid | $280 | $11,006141 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $132 | $3,083349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Sarasota
- Mark LupoSarasota$514K
- Jesus PerezSarasota$281K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.